Company intelligence / Profile preview

Lokon Pharma

Uppsala, Uppland, Swedenlokonpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

LOAd703 combined with standard of care chemotherapy has shown promising results with a 55% overall response rate in the highest dose cohorts in pancreatic cancer. Another arm combining LOAd703, chemotherapy and anti-PDL1 (atezolizumab) is near completion.

Therapeutic areas: Oncology
Modalities: Immunostimulatory gene therapyoncolytic adenoviruses
Industry: Biotech

Drug pipeline

6 assets

delolimogene mupadenorepvec

5 more assets in the full pipeline.

Request access →

Partnerships

Roche (announced in July 2019)

Beyond the preview

Go deeper on Lokon Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lokon Pharma.

Explore the full profile